If pharma companies were TV serials, Sanjivani Parenteral would be the one where every episode ends with “license abhi pending hai.” Between Red Sea pirates, container ghosts, and Indian regulators playing musical chairs with approvals, Q1 looked less like a business quarter and more like a reality show. Yet somehow, revenue still grew. Stick around—this script has both suspense and comedy.
2. At a Glance
Revenue ₹17.9 Cr, +8.9% YoY – Crawled forward, unlike their ships stuck in Suez.
EBITDA ₹2.7 Cr, +10.8% YoY – Margins flexed, like gym-goers before selfies.
PAT ₹1.7 Cr, Flat YoY – Profits stood frozen like buffering WiFi.
EBITDA Margin 15% – Clinging to stability harder than Indian parents to WhatsApp forwards.
Exports Mix 74% – Abroad loves them more than India does.
Debt ₹6 Cr – Tiny, but finance cost still nagged.
3. Management’s Key Commentary
Quote: “Pune plant commercial production by end of August/early September.” (Translation: Coming soon… like a Bollywood sequel delayed since 2019.)
Quote: “Prague JV has started small orders.” (Translation: Europe gave them trial homework; big results due Q4.)
Quote: “Logistics disrupted by Red Sea and container shortages.” (Translation: Basically, Neptune was their real CFO this quarter.)
Quote: “We added 8 new products this year.” (Translation: R&D is on steroids; sales impact TBD.)
Quote: “Margins stable at 15%.” (Translation: Flat is sexy, just ask your treadmill.)
